"Formulation and Drug Delivery."
Ajit Narang works for the Small Molecule Pharmaceutical Sciences Department of Genentech, Inc., in South San Francisco, CA responsible for the pharmaceutical development of new chemical entities through preclinical and early clinical stages. He has served as Adjunct Faculty at the Universities of Tennessee, Memphis, TN; University of Phoenix, Phoenix, AZ; University of Nebraska Medical Center, Omaha, NE; University of the Pacific, Stockton, CA; Campbell University, North Carolina; and Western Michigan University, Kalamazoo, MI. He serves as a panel member of the Biopharmaceutics Technical Committee (BTC) of the Pharmaceutical Quality Research Institute (PQRI) in Arlington, VA; a panel member of the International Pharmaceutics Excipient Council (IPEC) committees; Chair of the Formulation Design and Delivery (FDD) section of the American Association of Pharmaceutical Scientists (AAPS); a member of the Systems-based Pharmaceutics (SBP) alliance of the Process Systems Enterprise, Inc. (PSE) in London, UK; and a Scientific Advisor to the Editors of JPharmSci.
He holds over 15 years of pharmaceutical industry experience in the development and commercialization of oral and parenteral dosage forms and drug delivery platforms across preclinical through commercialization stages for both small and large molecule drugs. In addition to Genentech, he has worked for Bristol-Myers Squibb, Co., in New Brunswick, NJ; Ranbaxy Research Labs (currently a subsidiary of Daiichi Sankyo, Japan) in Gurgaon, India; and Morton Grove Pharmaceuticals (currently, Wockhardt USA) in Gurnee, IL. He holds undergraduate Pharmacy degree from the University of Delhi, India and graduate degrees in Pharmaceutics from the Banaras Hindu University, India and the University of Tennessee Health Science Center (UTHSC) in Memphis, TN.
Ajit has contributed to several preclinical, clinical, and commercialized drug products including NDAs, ANDAs, and 505B2s. He is credited with 54 peer-reviewed articles; 22 editorial contributions; 5 books; 10 patent applications; 47 invited talks; and 85 presentations at various scientific meetings.
Ajit’s current research interests are translation from preclinical to clinical and commercial drug product design; incorporation of QbD elements in drug product development; and mechanistic understanding of the role of material properties on product performance.